Autoimmune Thyroiditis
Autoimmune thyroiditis, also known as Hashimoto's thyroiditis or chronic lymphocytic thyroiditis, is a common autoimmune disorder. This page provides information on autoimmune thyroiditis diagnosis, including relevant clinical documentation, medical coding, ICD-10 codes, and healthcare best practices for managing this condition. Learn about symptoms, treatment options, and the importance of accurate medical coding for Hashimoto's thyroiditis in clinical settings.
Immune system attacks the thyroid gland, leading to hypothyroidism.
Fatigue, weight gain, constipation, dry skin, hair loss, depression.
Primary care, endocrinology clinics, family medicine practices.
ICD-10 Code Families
Complete code families applicable to E06.3
When to use each related code
| Description | When to use |
|---|---|
| Autoimmune attack of the thyroid gland, often leading to hypothyroidism. | Use when thyroid antibodies are present and patient has symptoms of hypothyroidism or goiter. Consider Hashimoto's as a synonym. |
| Underactive thyroid, producing insufficient thyroid hormones. | Code when patient has low T3/T4 levels and clinical signs of hypothyroidism, regardless of cause. Includes congenital and acquired. |
| Overactive thyroid, excessive thyroid hormone production. | Code when patient has high T3/T4 levels and symptoms such as weight loss, tremor, anxiety. Specify Graves' disease if confirmed. |
Best-practice checklist
- ✓Document thyroid antibody test results (e.g., TPOAb, TgAb).
- ✓Describe thyroid ultrasound findings (e.g., goiter, hypoechogenicity).
- ✓Note symptoms: fatigue, weight changes, constipation, dry skin.
- ✓Include TSH, Free T3, and Free T4 levels.
- ✓Specify Hashimoto's if confirmed by positive antibodies.
Common pitfalls to avoid
Coding Hashimoto's as unspecified thyroiditis (E06.9) leads to inaccurate severity and treatment reflection impacting reimbursement.
Concurrent goiter presence requires specific coding (E06.3). Missing documentation leads to undercoding and lost revenue.
While common, not all Hashimoto's patients have hypothyroidism. Documenting and coding both separately ensures clinical accuracy (E06.3, E03.9).
Best-practice tips
- 01Optimize ICD-10 coding E06.3 for Hashimoto's, ensuring CDI aligns with clinical findings.
- 02Document thyroid peroxidase (TPO) antibody & thyroglobulin (Tg) antibody levels for accurate diagnosis.
- 03Monitor TSH, Free T4, Free T3 levels per ATA guidelines, supporting medical necessity documentation.
- 04Assess for hypothyroid symptoms, documenting severity and impact for optimal patient care and coding.
- 05Consider ultrasound for thyroid morphology & size documentation, aiding E06.3 specificity for Hashimoto's.
Step-by-step checklist
- 1
Confirm TSH, Free T4 levels documented (ICD-10 E06.3)
- 2
Anti-TPO, anti-TG antibody status recorded for diagnosis (SNOMED CT 307922004)
- 3
Assess for goiter, hypothyroid symptoms in physical exam (E03.9)
- 4
Evaluate family history of autoimmune disease (ICD-10 Z82.4)
Ready-to-paste narrative
Patient presents with symptoms suggestive of autoimmune thyroiditis, also known as Hashimoto's thyroiditis or chronic lymphocytic thyroiditis. The patient reports experiencing fatigue, weight gain, constipation, dry skin, hair loss, and cold intolerance. Physical examination may reveal a diffusely enlarged, firm, and nontender thyroid gland. Laboratory evaluation demonstrates elevated thyroid peroxidase antibodies (TPOAb) and thyroglobulin antibodies (TgAb). TSH levels may be elevated, normal, or low depending on the stage of the disease. Free T4 and free T3 levels may be normal or low. Ultrasound imaging of the thyroid may show a heterogeneous echotexture with decreased vascularity, consistent with Hashimoto's thyroiditis. Differential diagnosis includes hypothyroidism from other causes, iodine deficiency, and subacute thyroiditis. The diagnosis of autoimmune thyroiditis is based on the combination of clinical presentation, positive thyroid antibody tests, and characteristic ultrasound findings. Treatment typically involves levothyroxine replacement therapy to normalize thyroid hormone levels and alleviate symptoms. Patient education regarding the chronic nature of the disease and the importance of medication adherence is crucial. Monitoring of TSH and free T4 levels will be performed to optimize the levothyroxine dosage. Follow-up appointments are scheduled to assess treatment response and manage potential complications such as myxedema coma or thyroid lymphoma, although the latter is rare. The patient's prognosis with appropriate management is generally good. ICD-10 code E06.3 is used for autoimmune thyroiditis.
Common questions and answers
What are the most effective diagnostic strategies for differentiating Autoimmune Thyroiditis (Hashimoto's Thyroiditis) from other forms of hypothyroidism in clinical practice?+
Differentiating Autoimmune Thyroiditis (Hashimoto's Thyroiditis) from other hypothyroid conditions requires a multi-faceted approach. Serum thyroid-stimulating hormone (TSH) and free thyroxine (FT4) levels are initial screening tests. Elevated TSH with low or normal FT4 suggests hypothyroidism. However, to pinpoint Hashimoto's, anti-thyroid peroxidase (TPO) antibodies and anti-thyroglobulin (TG) antibodies are essential. Positive TPO antibodies, highly sensitive for Hashimoto's, are often sufficient for diagnosis, especially when combined with the clinical picture. TG antibodies can be supportive but are less specific. Ultrasound can reveal a characteristically heterogeneous and hypoechoic thyroid gland, further supporting the diagnosis. Explore how combining these tests with patient history, including family history of autoimmune diseases and symptoms like fatigue and cold intolerance, can improve diagnostic accuracy. Consider implementing a diagnostic algorithm that includes TSH, FT4, TPO antibody testing, and selective use of TG antibody and ultrasound based on initial findings.
How should I manage subclinical hypothyroidism due to Hashimoto's Thyroiditis in asymptomatic patients, and when is levothyroxine therapy warranted based on current guidelines?+
Managing subclinical hypothyroidism in asymptomatic Hashimoto's patients involves careful monitoring and shared decision-making. Current guidelines generally recommend against levothyroxine therapy for asymptomatic individuals with mildly elevated TSH (typically between 4.0 and 10.0 mIU/L) and normal FT4. Regular monitoring of TSH and FT4, usually every 6-12 months, is crucial. Levothyroxine therapy should be considered if TSH levels persistently remain above 10 mIU/L, if anti-TPO antibodies are present with a TSH above the upper limit of normal even if below 10.0, or if the patient develops symptoms of hypothyroidism or goiter. Furthermore, women planning pregnancy with subclinical hypothyroidism and positive TPO antibodies should be considered for levothyroxine therapy. Learn more about the latest ATA and European Thyroid Association guidelines regarding the management of subclinical hypothyroidism in Hashimoto's patients. Consider implementing a patient-centered approach that incorporates patient preferences and individual risk factors.
What are the best strategies for long-term monitoring and follow-up care for patients with Hashimoto's Thyroiditis, including recommended frequency of TSH and FT4 assessments, and potential complications to watch for?+
Long-term management of Hashimoto's Thyroiditis focuses on optimizing thyroid hormone levels and monitoring for disease progression and potential complications. Once levothyroxine therapy is initiated, TSH and FT4 levels should be checked every 6-8 weeks until stable, then every 6-12 months thereafter. Clinicians should be vigilant for both overtreatment and undertreatment, adjusting levothyroxine dosage as needed based on TSH and FT4 values as well as patient symptoms. Patients with Hashimoto's are at an increased risk of developing other autoimmune diseases, such as type 1 diabetes and celiac disease, so consider screening for these conditions if clinically indicated. Additionally, long-term monitoring should include periodic assessment for thyroid nodules and thyroid cancer, as Hashimoto's increases the risk of both. Learn more about the importance of patient education regarding lifestyle modifications, potential drug interactions with levothyroxine, and the need for ongoing monitoring and open communication with their healthcare provider.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.